Answers are grounded in this paper and cite their sources.
Matrix metallopeptidase 1 ( MMP1 ), a secreted collagenase, is linked to aggressive lung adenocarcinoma (LUAD); its cellular origin and stage-specific function remain unclear. A 39-gene metabolic reprogramming signature (MetabRisk) was derived from 1,045 lipid-metabolism genes in TCGA-LUAD, benchmarked across five screening cohorts and validated in eight independent cohorts; MMP1 was profiled for expression, prognosis, protein abundance, cell source (seven cohorts; 837,814 cells), spatial distribution and phenotype, and silenced by siRNA. MetabRisk reached an internal cross-validated C-index of 0.618 and a pooled external C-index of 0.629 (95% CI 0.605–0.652), and highlighted MMP1 . MMP1 was tumor-upregulated (log 2 FC = 4.62). At cohort-median stratification, higher expression was associated with shorter progression-free interval in TCGA-LUAD (HR = 1.31, p = 0.029) and with shorter survival in three of the five screening cohorts (p = 0.014–0.036), whereas analysis as a continuous variable was not significant in TCGA-LUAD (HR 1.02–1.08, p = 0.31–0.82); the association is therefore modest and cut-point-dependent, and single-gene survival p values are not adjusted for the number of endpoints or cohorts examined. Protein was elevated in 207 CPTAC pairs. MMP1 + spot fractions rose from pre-invasive to invasive LUAD (median 4.18%; p = 1.8 × 10 –6 ) and were ~11-fold higher among epithelial cells at the invasive edge in a descriptive, exploratory comparison of three patients; MMP1+ cells were restricted to tumor tissue and comprised malignant-epithelial and CAF fractions in proportions that varied across cohorts. Patient-matched brain metastases expressed less MMP1 than primary tumors (23 pairs, p = 0.010). MMP1 + malignant cells showed higher nuclear-encoded OXPHOS and fatty-acid-oxidation module scores; MMP1 knockdown in A549 and PC-9 cells suppressed proliferation, migration and invasion. MMP1 therefore contributes to extracellular matrix remodeling and invasion in LUAD and merits preclinical evaluation as a candidate therapeutic target in invasive-stage LUAD.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: